Alpheus Medical Clinches $52M Series B to Transform Non-Invasive Therapy for Glioblastoma Treatment

Alpheus Medical, Inc., a trailblazer in innovative cancer treatment based in Oakdale, Minnesota, today announced a monumental funding achievement, having successfully raised $52,000,000. This significant capital infusion is set to accelerate the development of its groundbreaking sonodynamic therapy platform, which is designed to target solid body cancers. At the heart of this platform is a novel, non-invasive drug-device combination intended for outpatient treatment of recurrent glioblastoma multiforme (rGBM), a formidable and aggressive brain cancer. By integrating cutting-edge technology with a deep commitment to improving patient outcomes, Alpheus Medical is poised to redefine therapeutic approaches in neuro-oncology. The company’s pioneering work is not only supported by collaborations with internationally renowned experts in the field but also bolstered by the endorsement of industries’ leading advocacy groups such as the American Cancer Society and the National Brain Tumor Society. The newly secured funds will be strategically allocated to further refine the sonodynamic therapy platform, expand clinical trials, and navigate the complex path toward regulatory approval. In addition to enhancing its current product pipeline, Alpheus Medical plans to invest in fostering additional research initiatives that explore similar non-invasive treatment methodologies, potentially opening up new avenues for combating various forms of cancer. This funding milestone represents a remarkable vote of confidence in the company’s vision and technological expertise, setting the stage for transformative advancements in cancer treatment and a brighter future for patients battling some of the most challenging oncological diseases.